Cisplatin is a chemical compound with formula cis-[Pt(NH3)2Cl2]. It is a coordination complex of platinum that is used as a chemotherapy medication used to treat a number of cancers. Structurally it is a square planar platinum II complex that undergoes chloride displacement in low chloride environments to form aquated species that bind nucleophilic sites on DNA leading primarily to intrastrand crosslinks, replication arrest and apoptosis. Clinically it is administered intravenously, shows high plasma protein binding and predominantly renal elimination, and is established in curative and palliative regimens for testicular cancer, ovarian cancer, cervical cancer, bladder cancer and selected head and neck and lung cancers. Key clinical considerations include dose-dependent nephrotoxicity, ototoxicity, and cumulative myelosuppression, and dosing protocols commonly use aggressive hydration and electrolyte management to reduce renal injury.
Parent: Cisplatin
Commercial active pharmaceutical ingredient and finished product specifications are controlled to limit related platinum species and nonvolatile and volatile impurities. Typical related compounds of concern include the trans isomer transplatin, partially hydrolyzed mono-aqua and di-aqua platinum species, polymeric platinum-oxygen or -chloride aggregates, and traces of residual inorganic salts or heavy metals. Typical supplier and pharmacopeial style specification ranges used in quality control are transplatin less than about 0.5% w/w, mono-aqua hydrolysis products less than about 0.5 to 1.0% w/w, di-aqua species below about 0.1 to 0.5% w/w, other unidentified organoplatinum impurities collectively below 0.5 to 1.0% w/w, and total heavy metal residues controlled to low ppm levels depending on the method; acceptance is confirmed by stability-indicating HPLC/ICP-MS and ion chromatographic assays. Exact limits vary by manufacturer and regulatory monograph and are verified by certificates of analysis for each batch.
Cisplatin is used intravenously to treat various solid tumors; primary indications include testicular, ovarian, cervical and bladder cancers, and it is also employed in selected non-small cell lung, head and neck, and other combination regimens. It is a core drug in curative regimens for many testicular cancers and in combination therapies for ovarian and other malignancies.
The most clinically important serious side effect is nephrotoxicity, which can be dose limiting and may lead to acute kidney injury; other major toxicities include irreversible ototoxicity, cumulative peripheral neuropathy and myelosuppression. Adequate hydration, electrolyte monitoring and dose adjustments are standard measures to mitigate renal injury.
Cost varies by formulation, vial strength, brand and procurement channel; in India generic cisplatin supplied for intravenous use is generally low cost compared with many newer agents, with retail and institutional prices differing by region and quantity purchased. For an accurate current price, check local hospital pharmacies, approved distributors or government procurement catalogs because published prices change frequently.
There is no single strongest chemotherapy agent; potency and clinical usefulness depend on tumor type, regimen and therapeutic index. Cisplatin is highly effective for certain cancers such as testicular and ovarian tumors, but other agents or combinations may be more effective or less toxic for different malignancies. Treatment selection balances efficacy, resistance patterns and toxicity.
